AIHealthcare

Iktos is a privately held French artificial-intelligence and biotechnology company focused on AI- and robotics-enabled drug discovery. Founded in 2016, it develops generative deep-learning systems for de novo small-molecule design and multi-parameter optimization, AI-powered retrosynthesis planning, and automated synthesis and biological testing. Its principal software platforms include Makya for generative molecular design and Spaya for retrosynthesis planning; the company also offers integrated discovery collaborations and is developing an AI-orchestrated robotics platform. Iktos serves pharmaceutical and biotechnology companies and has announced collaborations with organizations including Servier, Pierre Fabre Laboratories, Italfarmaco, and Chemspeed. Its stated differentiation is the integration of computational molecule design with automated laboratory execution and testing, alongside an expanding internal pipeline in areas including oncology, inflammatory and autoimmune diseases, and obesity/metabolism. Public sources describe Iktos as a notable participant in the AI drug-discovery market, but no independently verified valuation or market-share figure was identified.